Kornimate/medical-research-clean huggingface dataset:
microvention aneurysm & stroke real-life data collection

Conditions: Intracranial Aneurysm; Intracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm Lesion; Aneurysmal Subarachnoid Hemorrhage

Summary: the maestro-1 registry is a post-market, single-arm, non-interventional, multicenter registry

electronic platform to collect real-world clinical data, evaluate and periodically report safety and effectiveness of ce approved and commercially available microvention implant devices used for the endovascular treatment of intracranial aneurysms.

Eligibility criteria:
inclusion criteria: * patient or legally authorized representative (lar) is informed of the data collection and gives non-opposition or consent prior to the data collection in accordance with institutional and geographic requirements. * patient is treated for a ruptured or unruptured intracranial aneurysm using a commercially available microvention implant device as the primary treatment device and the decision to use this device has been made by the treating physician outside the context of the maestro-1 study. exclusion criteria: * patient is or is expected to be inaccessible for follow-up. * patient is participating or intends to participate in another study that changes the site practice. * patient has been previously enrolled into the maestro-1 study.

Keywords: endovascular treatment stent flow diverter hydrocoil coil implantable device fred lvis web
perioperative outcome of corticosteroids in transforaminal endoscopic lumbar discectomy

Conditions: Lumbar Disc Herniation

Summary: the endoscopic discectomy has rapidly developed and increased need by patients. this procedure is widely performed by interventional pain physicians as well as by spine surgeons because it requires no general anesthesia or admission to a hospital. many studies were reported that corticosteroid injection can inhibit persistent postoperative pain in lumbar discectomy. however, data of perioperative epidural steroids after an endoscopic discectomy is lacking.

to examine whether corticosteroid administered epidural space in patients undergoing endoscopic lumbar discectomy reduces postoperative morphine consumption, back and leg pain relief, improves functional disability comparing to placebo

Eligibility criteria:
inclusion criteria: * lumbar disc herniation patient age 20-45 year-old who have symptom duration was at least 6 weeks and conservative treatment failed exclusion criteria: * refuse to participate and inform consent, previous spinal surgery, history of allergic to steroid
body-oriented therapy for women in sud treatment

Conditions: Substance Use Disorder

Summary: the long-term objective of this study is to improve women's substance use disorder (sud) treatment. the immediate project goal is to test the efficacy of an innovative mind-body intervention, mindful awareness in body-oriented therapy (mabt) to reduce substance use relapse among women in sud treatment. a novel mind-body approach, mabt combines a hands-on (manual) approach with mind-body psycho-education approaches of interoceptive training and mindfulness to develop somatically-based self-care skills and to facilitate emotion regulation. a three-group, randomized clinical trial using repeated measures, this project will enroll and randomize 225 women to one of three groups, mabt + treatment-as-usual (tau) (n=75), tau only (n=75), and women's health education (whe) + tau (to control for time and attention) (n=75). study conditions will be compared at baseline, post-intervention, and at 6 and 12 month follow-up. the primary aim is to test the hypothesis that mabt will result in reduced substance use and related health outcomes compared to tau and to whe+ tau at 12 month follow-up. the second aim is to examine hypothesized underlying mechanisms of mabt. female outpatients in two diverse community treatment facilities, serving racially diverse patients, will be recruited for study participation. this study builds on promising preliminary evidence of mabt feasibility and acceptability in substance use disorder treatment for women, and addresses the need for more clinical research aimed at improving sud treatment outcomes for women.


Eligibility criteria:
inclusion criteria: * 1) female, 2) enrolled in intensive outpatient (iop) with at least 8 weeks remaining in planned sud treatment program, 3) agrees to forgo (non-study) manual therapies (e.g.,massage) and mind-body therapies (e.g., mindfulness meditation) for 3 months (baseline to post-test); 4) willing to sign release for access of electronic medical records; 5) fluent in english; and 6) can attend mabt and whe sessions when offered. exclusion criteria: * ) untreated psychotic diagnosis or symptoms, using modules from the mini international neuropsychiatric interview; 2) unwilling or unable to remain in treatment for the duration of the trial (includes planned relocation, pending incarceration, planned surgical procedures, etc.); 3) cognitive impairment, to be assessed with an informed consent quiz, followed by the mini-mental status exam (mmse), a common screening tool in sud treatment studies, if there is demonstrated difficulty comprehending the consent; or 4) currently pregnant.

Keywords: substance use disorders complementary therapies women mind-body therapies behavior and behavior mechanisms
a single-dose, open-label, study to evaluate the sustainability of the effects of syn-010 in patients with ibs-c

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)

Summary: a single-dose, open-label, extension study to evaluate the sustainability of the effects of syn-010 in patients with irritable bowel syndrome with constipation

this is a phase 2, multi-center, open-label study. up to sixty subjects with irritable bowel syndrome with constipation who are between the ages of 18 and 65, inclusive, will be enrolled. subjects must have completed the previous sb-2-010-001 study. the entire duration of the study may be up to 57 days (from enrollment to the post end-of-study \[eos\] visit telephone call).

Eligibility criteria:
inclusion criteria: * subject has completed study sb-2-010-001. * subject must be willing to abstain from or discontinue the use of any laxatives and any prescription and over-the-counter medications or supplements intended to treat constipation from the time of screening to the end of the study, except as permitted in this protocol. * subject must agree to refrain from making any lifestyle changes that may affect ibs-c symptoms from the time of screening to the end of the study. exclusion criteria: * subject has taken ibs treatments (prescription or over-the-counter), proton pump inhibitors, laxatives, antibiotics. * subject did not complete study sb-2-010-001 or more than 7 days have elapsed since the subject's last dose of study drug in that study. * subject reports loose (mushy) or watery stools (bristol stool form scale \[bsfs\] score of 6 or 7) in the absence of any laxative, or has a bsfs score of 6 for more than 1 spontaneous bowel movement (sbm) or a bsfs score of 7 for any sbm during the last 7 days of diary reporting for study sb-2-010-001. * subject has any abnormal laboratory results, electrocardiogram (ecg) findings, or physical examination findings deemed clinically significant by the investigator at the study sb-2-010-001 end-of-study visit.
phase ii study of pre-operative chemotherapy in patients with resectable local-regional carcinoma of esophagus

Conditions: Esophageal Diseases

Summary: this study is designed pre-operative for patients with resectable, local-regional carcinoma of the esophagus.

this study is designed for patients with resectable, local-regional carcinoma of the esophagus. in a pre-operative setting, chemotherapy with taxol, cisplatin, and 5-fluorouracil will be administered followed by g-csf.

Eligibility criteria:
inclusion criteria: * measurable disease with resectable local-regional carcinoma of the esophagus. 18 years of age or older. exclusion criteria: * pregnant or lactating. non-resectable local-regional carcinoma of the esophagus.

Keywords: esophageal diseases
study to evaluate the efficacy and safety of oral rp7214, a dhodh inhibitor, in patients with symptomatic mild covid-19 infection.

Conditions: SARS-CoV-2 Infection

Summary: this is a randomized, double-blind, placebo-controlled study of rp7214 in patients with symptomatic mild sars-cov-2 infection, having at least one high-risk feature (e.g., age \> 60 years, hypertension, diabetes mellitus, chronic lung disease, chronic kidney disease, liver disease, cerebrovascular disease, obesity, cancer) for developing severe covid-19 illness.


Eligibility criteria:
inclusion criteria: 1. willing and able to provide informed consent. 2. males and females of ≥ 18 years of age 3. patient with mild covid-19 infection having ≥ 1 symptoms. 4. laboratory confirmed covid-19 infection by reverse transcription polymerase chain reaction (rt-pcr) in nasopharyngeal sample (within 72 hours prior to randomization). 5. patient should have at least one pre-existing high-risk feature for developing severe covid-19 illness. 6. ability to swallow and retain oral medication. 7. male patient who is surgically sterile, or who is willing to agree to use a contraceptive measure. 8. women of childbearing potential should be willing to use a medically acceptable method of contraception. 9. willing to receive telephone calls or have videoconferences with study team personnel. 10. willing and able to understand the nature of this study, comply with the study procedures and follow-up procedures as per the study protocol. exclusion criteria: 1. patient with asymptomatic covid-19 infection. 2. patient who has experienced the onset of any of covid-19 symptoms \> 5 days at the time of randomization. 3. moderate to severe covid-19 infection 4. patient with covid-19 re-infection 5. subjects who are severely immunocompromised 6. subjects with autoimmune diseases 7. patients with any bleeding disorder e.g., hemophilia and von willebrand disease. 8. current use of other dhodh inhibitors including teriflunomide or leflunomide. 9. patients who are on or immediately require covid-19 directed treatment such as antivirals, immunomodulatory treatment, convalescent plasma, oral/ intravenous steroids, or monoclonal antibodies at the time of screening. 10. patients who have had received one or two doses of vaccine for covid-19. 11. patients participating in another clinical study or use of any investigational product within 4 weeks or 5 half-lives of the drug, whichever is longer, before the date of dosing
safety and tolerability study of the taris placebo system

Conditions: Healthy

Summary: the aim of this protocol is to evaluate the tolerability of the taris placebo system for the development program and to provide key safety and tolerability data for the taris platform.


Eligibility criteria:
inclusion criteria: * healthy female volunteers, 18 to 55 years of age * body weight \>100 lbs and bmi (body mass index) within the range 18-30 kg/m2 * a score of less than 11 on the pelvic pain/urgency-frequency scale (puf) exclusion criteria: * presence of any bladder or urethra anatomical feature that, in the opinion of the investigator, might prevent the safe placement, indwelling use, or removal of the taris placebo system * history of significant urogenital surgery (any type of bladder suspension, prolapse repair, incontinence procedure, or vaginal hysterectomy) * history of kidney stone formation * chronic or recurring bacterial or viral infections of the urogenital system

Keywords: taris placebo bladder interstitial cystitis normal healthy volunteers
biological markers of response to treatment in major depressive disorder

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an fda approved antidepressant medication (either citalopram or escitalopram).

major depressive disorder (mdd) is a severe form of depression. mdd can significantly interfere with an individual's thoughts, behavior, mood, and physical health. people who suffer from mdd often experience feelings of worthlessness; they may feel hopeless and may be unable to cope with problems in their life. in addition, they often experience sleep disruption, loss of appetite, and chronic pain. it often takes several weeks to find out if an antidepressant medication is going to work for someone. this research study aims to identify tests that are able to predict if a medication will work, even before a person starts to feel better. the first test is a measurement of the blood protein brain-derived neurotrophic factor (bdnf), which is involved with brain cell growth. the second test is a quantitative electroencephalogram (qeeg), which measures brain activity. the study lasts for 8 weeks and involves 5 total visits to the clinic. throughout the study, all subjects will receive either escitalopram (lexapro) or citalopram (celexa) on the basis of the study doctor's clinical judgment. the dose of the medications can be increased at any point in time if the study doctor thinks it is appropriate. after the first screen visit (which lasts about 3 hours), each subsequent half-hour visit will involve a 2-tablespoon blood draw to measure bdnf levels, as well as a qeeg in which small, painless electrodes are stuck to the subject's forehead and electrical activity of the brain is measured. at the end of the 8 weeks, subjects are offered 3 months of free follow-up care, including medications.

Eligibility criteria:
inclusion criteria: * ages 18-65 * meet criteria for current major depressive disorder * antidepressant medication-free for at least 2 weeks prior to the start of the study exclusion criteria: * pregnant or breastfeeding women * anyone who is suicidal * anyone with an unstable medical condition (cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological), substance abuse problem within the past 6 months, psychoses (past or current), hypothyroidism, or hypomania * anyone currently taking an ssri * past intolerance to lexapro or celexa

Keywords: depression biology
evaluation of gastric juice samples during standard gastroscopy procedure

Conditions: Gastrointestinal Bleeding

Summary: development of a new diagnostic detection tool for gastrointestinal bleeding.

literature does not support enough data/knowledge regarding stomach bleeding hb levels in pathological situations and/or stomach bleeding levels following biopsy. it is important to understand the approximate concentration level of stomach bleeding before proceeding with technology development to insure this technology is capable of detecting such blood levels.

Eligibility criteria:
inclusion criteria: * male or female subjects ≥ 18 years old. * subject is scheduled for egd endoscopy which includes biopsy, or, * subject is scheduled for egd endoscopy following a bleeding event. exclusion criteria: * subject is either not competent or not willing to provide written informed consent.

Keywords: gastric juice stomach gi gastric juice samples with presence of blood.
concomitant epicardial pulmonary vein isolation in patients with atrial fibrillation undergoing elective cardiac surgery

Conditions: Atrial Fibrillation

Summary: recent studies demonstrated that radiofrequency isolation of the pulmonary veins (pvi) is a superior alternative to antiarrhythmic drug therapy in patients with symptomatical paroxysmal atrial fibrillation (af). a substantial proportion of patients undergoing elective cardiac surgery also suffer from atrial fibrillation. no evidence exists if epicardial pvi is beneficial in patients with a history of af undergoing coronary bypass surgery (cabg) for the concomitant treatment of af. the investigators aim to establish the effectiveness of incorporating epicardial pulmonary vein isolation into elective cardiac surgery.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age * ehra class ≤ 2 * documented history of paroxysmal, persistent, longstanding persistent or newly-diagnosed af prior to admittance for cardiac surgery * patients will have elective coronary surgery planned able of providing informed consent exclusion criteria: * patients ≥70 years of age * pregnancy patients with contraindications for oral anticoagulant agents * patients undergoing emergency operation * patients undergoing concomitant valve replacement * severely enlarged la (\>50 mm) on echocardiography * prior af ablation or af surgery
evaluation of the effect of endoscopic urethral procedures applied after radical prostatectomy on urinary incontinence

Conditions: Prostate Cancer; Incontinence

Summary: the researchers investigated whether endoscopic retrograde urethral interventions applied for various reasons after radical prostatectomy (rp) operation cause a change in urinary incontinence (ui) level, and if there is a change, whether it changes according to the endoscopic procedure time and the endoscopic instrument used.

localized prostate cancer is usually treated with rp. the most common complications after rp are erectile dysfunction (ed) and ui. after rp, some patients may require retrograde endoscopic urethral intervention. in this study, researchers investigated whether there is a change in the ui level in patients that underwent retrograde urethral intervention after rp and whether this change was affected by the duration of the procedure and type of endoscopic device used. methods: eighteen patients were included in the study. the patients were divided into 3 groups based on the endoscopic device used: group 1 rigid cystoscopy, group 2 flexible cystoscopy, and group 3 semi-rigid ureterorenoscopy (urs). the turkish version of the international consultation on incontinence questionnaire-urinary incontinence short form (iciq-sf) and the number of pads used daily was questioned before the endoscopic procedure and 1 month after the procedure.

Eligibility criteria:
inclusion criteria: * patients who have undergone radical prostatectomy * patients that had undergone an endoscopic procedure 1 year after rp exclusion criteria: * patients with urinary tract infection before the endoscopic procedure, * urinary tract infection at 1st month follow-up * central neurological deficit * history of adjuvant radiotherapy after rp * bladder neck stenosis and urethral stenosis * patients that had undergone endoscopic urethral intervention before this scheduled procedure * patients who had a double j stent inserted during the endoscopic procedure and required a second endoscopic intervention * patients that required the use of bipolar or monopolar cautery

Keywords: prostate cancer urinary incontinence endoscopic surgical procedures
is the volume of the caudate nuclei associated with area of secondary hyperalgesia?

Conditions: Pain; Secondary Hyperalgesia; Healthy Volunteers; Magnetic Resonance Imaging

Summary: the purpose of this prospective study is to investigate the degree of association between the volume of important pain-relevant structures in the brain and the size of the areas of secondary hyperalgesia.

the healthy study participants will be included from the cohort of a previous study (nct02527395) where areas of secondary hyperalgesia, heat pain detection thresholds, pain during 1 min. thermal stimulation and test results from the pain catastrophizing scale and the hospital anxiety and depression score will be retrieved. the study consists of 1 study day. the study day will be conducted at a maximum of 2 months and a minimum of 2 weeks after the completion of the previous study (nct02527395).the results of the previous study (nct02527395) will be blinded until all participants have completed the study day. all study participants will complete a mri-scan of the brain. the mri scans will be performed with a siemens magnetom verio 3 tesla, with b17 software, and a 32-channel head coil. the mri-scan sequence is as follows: * 3d localiser * 3d t1 weighted iso * ax diffusion tensor imaging * ax epi resting state fmri * ax gre field map * ax epi asl * ax t2-weighted blade * ax t2-weighted flair * ax t2-weighted\* gre total mri-scan time is estimated to approximately 40 minutes.

Eligibility criteria:
inclusion criteria: * age \>18 years and \<35 years * speak and understand danish * male sex * study participants who have understood and signed the informed consent * no prescription medicine during the last 30 days. * have participated and completed the study with the identifier: nct02527395. exclusion criteria: * study participants that cannot cooperate to the test. * study participants who have a weekly intake of \>21 units of alcohol, or a have consumed \>3 units of alcohol within 24 hours before experimental day. * study participants with a substance abuse, assessed by the investigator. * study participants, who have consumed analgesics less than 3 days before experimental day. * study participants, who have consumed antihistamines less than 48 hours before experimental day. * study participants, who have consumed antidepressant medication during the last 30 days before experimental day. * study participants with chronic pain. * study participants with neurological illnesses. * study participants with psychiatric diagnoses. * study participants with a body mass index of \>30 kg/m2 or \<18 kg/m2 * study participants with contraindications to mri * study participants that decline information regarding potential pathological findings in relation to the mri. * study participants that have any kind of trauma resulting in pain and administration of analgesics in the period between experimental pain testing and mri-scan. * study participant that experience a head trauma in the period between the experimental pain testing and the mri-scan.

Keywords: pain secondary hyperalgesia healthy volunteers magnetic resonance imaging
program for cardiovascular prevention and randomized clinical trial

Conditions: Hypertension

Summary: develop and evaluate a model of organization and management in the management of patients with cardiovascular risk factors (hypertension, diabetes mellitus, smoking, obesity, physical inactivity, dyslipidemia and family history) in primary care aimed at the compliance, control and treatment effectiveness.


Eligibility criteria:
inclusion criteria: * diagnosis of hypertension (\> 140/90 mmhg) * age \> 40 years * sitting: usf da restinga e extremo sul - usf chapéu do sol and usf paulo viaro exclusion criteria: * institutionalized individuals * patients with mental illness or disabling chronic illnesses * users of health services belonging to the supplementary health * individuals with life expectancy less than 1 year
painted playgrounds: aim 2: assessments

Conditions: Childhood Obesity

Summary: the painted playgrounds aim 2 (assessment) project will examine the effects of a stenciling intervention aimed at increasing physical activity and improving fundamental motor skill functioning of preschool aged children. 72 children from local licensed childcare centers will participate in individual assessments at baseline and follow-up 6-8 weeks later. assessments include height/weight, surveys and wearing a physical activity monitor (accelerometer) for 7 days. a parent/legal guardian will provide consent for their child to participate and will also complete a brief survey about their child's lifestyle and habits.


Eligibility criteria:
inclusion criteria: * a child who attends a childcare center enrolled to aim 1. * a child who is ≥ 3 years and ≤ 6 years old * your child will continue to attend this same childcare center for the duration of the study. exclusion criteria: • parent/legal guardian is unwilling to provide written informed consent